Last update 22 Feb 2025

Adalimumab Biosimilar(Nippon Kayaku)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms-
Target
TNF-α
Action-
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Therapeutic Areas
Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [6]
Active Indication
Ankylosing SpondylitisArthritis, PsoriaticBehcet Syndrome+ [9]
Inactive Indication-
Originator Organization
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
Active Organization
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (25 Sep 2023),
Ankylosing SpondylitisArthritis, PsoriaticBehcet Syndrome+ [9]
Regulation-
Login to view timeline

Structure/Sequence

Related

100 Clinical Results associated with Adalimumab Biosimilar(Nippon Kayaku)
Login to view more data
100 Translational Medicine associated with Adalimumab Biosimilar(Nippon Kayaku)
Login to view more data
100 Patents (Medical) associated with Adalimumab Biosimilar(Nippon Kayaku)
Login to view more data
100 Deals associated with Adalimumab Biosimilar(Nippon Kayaku)
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ankylosing Spondylitis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Arthritis, Psoriatic
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Behcet Syndrome
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Colitis, Ulcerative
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Crohn Disease
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Panuveitis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Plaque psoriasis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Pustular psoriasis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Rheumatoid Arthritis
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Uveitis, Intermediate
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Uveitis, Posterior
Japan
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd.
25 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free